GGO Vergunningendatabase

Zoekcriteria

1. Rechtspersoon:
2. Uitgangs-organisme:
3. Procedure: Alle MA IG IM-MV IM-L
4. Dossiernummer:

1. Status: Alle Ter inzage Vergunning onherroepelijk In behandeling Werkzaamheden gestart Besluit genomen Kennisgeving niet ingestemd Besluit geweigerd Procedure afgerond Intrekkingsbesluit onherroepelijk Teruggetrokken Vergunning verleend Ontwerpbesluit genomen
2. Datum vergunning vanaf:
3. Datum vergunning t/m:

1. Trefwoorden:

Zoekresultaat

IM-MV 16-007_012	UMCG	Testing the safety and efficacy of KTE-C19 in patients with refractory or relapsed B-cell malignancies	08-04-2024	Vergunning verleend
IM-MV 23-014_000	Erasmus MC	Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination with CD123 Target Module (R-TM123) for the Treatment of Patients with Selected Hematologic MalignanciesPositive for CD123	08-04-2024	Vergunning verleend
IM-MV 23-015_000	UMCG	Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination with CD123 Target Module (R-TM123) for the Treatment of Patients with Selected Hematologic Malignancies Positive for CD123	08-04-2024	Vergunning verleend
IM-MV 23-017_000	Amsterdam UMC	Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination with CD123 Target Module (R-TM123) for the Treatment of Patients with Selected Hematologic MalignanciesPositive for CD123	08-04-2024	Vergunning verleend
IM-MV 24-001_000	Amsterdam UMC	Local oncolytic adenovirus administration to sensitize the immune microenvironment of esophageal adenocarcinoma for chemoradiation		Ontwerpbesluit genomen